PepGen Inc., (PEPG) News

PepGen Inc., (PEPG): $2.30

0.12 (-4.96%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add PEPG to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#133 of 337

in industry

Filter PEPG News Items

PEPG News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PEPG News Highlights

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

Latest PEPG News From Around the Web

Below are the latest news stories about PEPGEN INC that investors may wish to consider to help them evaluate PEPG as an investment opportunity.

All You Need to Know About PepGen (PEPG) Rating Upgrade to Buy

PepGen (PEPG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | January 8, 2025

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

BOSTON, December 16, 2024--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company received a clinical hold notice from the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application to initiate the CONNECT2-EDO51 clinical trial in patients with Duchenne muscular

Yahoo | December 16, 2024

PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development

BOSTON, November 21, 2024--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen’s 2024 Inducement Plan as a material inducement to employment to its newly appointed Senior Vice President, Clinical Development, Steve Han, MD, PhD, MMSc.

Yahoo | November 21, 2024

PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

BOSTON, November 07, 2024--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended September 30, 2024.

Yahoo | November 7, 2024

We're Keeping An Eye On PepGen's (NASDAQ:PEPG) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | November 6, 2024

PepGen to Participate in Upcoming Investor Conferences

BOSTON, November 04, 2024--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences:

Yahoo | November 4, 2024

PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society

BOSTON, October 08, 2024--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company will be presenting a short oral presentation as well as five posters at the 29th Annual Congress of the World Muscle Society (WMS), being held October 8-12, 2024 in Prague, Czech Republic.

Yahoo | October 8, 2024

PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors

BOSTON, September 19, 2024--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that Christopher Ashton, PhD, intends to retire from the Board of Directors effective September 30, 2024. Dr. Ashton has served on PepGen's Board of Directors since December 2019 and was a member of the audit and compensation committee

Yahoo | September 19, 2024

PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development

BOSTON, August 20, 2024--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen’s 2024 Inducement Plan as a material inducement to employment to its newly appointed Executive Vice President, Research & Development, Paul D. Streck, M.D., MBA.

Yahoo | August 20, 2024

PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development

BOSTON, August 20, 2024--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development (R&D), effective immediately. Dr. Streck will join the PepGen Executive Team and will be responsible for leading the R&D organization.

Yahoo | August 20, 2024


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!